{"id":"bg00012-dmf","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Flushing"},{"rate":"30-40","effect":"Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)"},{"rate":"5-10","effect":"Lymphopenia"},{"rate":"5-10","effect":"Elevated liver enzymes"},{"rate":"10-15","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL555694","moleculeType":"Small molecule","molecularWeight":"661.66"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dimethyl fumarate is a fumaric acid ester that crosses the blood-brain barrier and activates Nrf2, a transcription factor that upregulates antioxidant and anti-inflammatory genes. This reduces reactive oxygen species production and pro-inflammatory cytokine release in the central nervous system, thereby decreasing neuroinflammatory damage in multiple sclerosis. The drug also modulates immune cell populations, reducing pro-inflammatory T cells and promoting regulatory T cells.","oneSentence":"BG00012 (dimethyl fumarate) activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway to reduce oxidative stress and neuroinflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:05.208Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis (RRMS)"},{"name":"Primary progressive multiple sclerosis (PPMS)"}]},"trialDetails":[{"nctId":"NCT07483632","phase":"PHASE3","title":"A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)","status":"NOT_YET_RECRUITING","sponsor":"Biogen","startDate":"2026-11-16","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":185},{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT06551519","phase":"","title":"A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-28","conditions":"Multiple Sclerosis","enrollment":700},{"nctId":"NCT05344469","phase":"","title":"A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":"Relapsing Multiple Sclerosis","enrollment":800},{"nctId":"NCT07258394","phase":"PHASE3","title":"Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Nanjing Medical University","startDate":"2026-01-27","conditions":"Type 1 Diabetes","enrollment":90},{"nctId":"NCT04788615","phase":"PHASE3","title":"Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-23","conditions":"Multiple Sclerosis","enrollment":185},{"nctId":"NCT04821596","phase":"NA","title":"Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2020-07-13","conditions":"Multiple Sclerosis","enrollment":77},{"nctId":"NCT04292080","phase":"PHASE2","title":"Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-02-07","conditions":"Age-related Macular Degeneration (AMD)","enrollment":90},{"nctId":"NCT06843382","phase":"","title":"Real-world Experience of Oral Agents On Fatigability in Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"TC Erciyes University","startDate":"2025-11-20","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT05767736","phase":"","title":"A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2024-06-08","conditions":"Multiple Sclerosis","enrollment":10500},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT07189325","phase":"PHASE3","title":"A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-09","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy","enrollment":250},{"nctId":"NCT05962177","phase":"NA","title":"Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2023-09-11","conditions":"Multiple Sclerosis","enrollment":400},{"nctId":"NCT03535298","phase":"PHASE4","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-01-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":800},{"nctId":"NCT07138833","phase":"PHASE4","title":"A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS)","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical (Hainan) Co., Ltd.","startDate":"2025-09","conditions":"Relapsing Multiple Sclerosis","enrollment":50},{"nctId":"NCT06715605","phase":"PHASE2","title":"A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS","status":"WITHDRAWN","sponsor":"University Hospital, Antwerp","startDate":"2025-04-30","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT05658497","phase":"","title":"Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)","status":"RECRUITING","sponsor":"Biogen","startDate":"2023-10-27","conditions":"Multiple Sclerosis","enrollment":908},{"nctId":"NCT02283853","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-08-28","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":156},{"nctId":"NCT05658484","phase":"PHASE4","title":"A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China","status":"COMPLETED","sponsor":"Biogen","startDate":"2023-06-09","conditions":"Multiple Sclerosis","enrollment":60},{"nctId":"NCT02975349","phase":"PHASE2","title":"A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2017-03-07","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":267},{"nctId":"NCT03193866","phase":"","title":"COMparison Between All immunoTherapies for Multiple Sclerosis.","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2017-06-02","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":3526},{"nctId":"NCT03331835","phase":"PHASE4","title":"A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-11-03","conditions":"Psoriasis Vulgaris","enrollment":210},{"nctId":"NCT06850597","phase":"PHASE2","title":"Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2024-10-28","conditions":"MCI, MCI-AD, Early Stage Alzheimer's Disease, Alzheimer's Disease","enrollment":30},{"nctId":"NCT05269888","phase":"","title":"Covid-19 Vaccine Immune Response in Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospitals of North Midlands NHS Trust","startDate":"2022-02-16","conditions":"Multiple Sclerosis","enrollment":240},{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":"Psoriasis, Psoriatic-arthritis","enrollment":3500},{"nctId":"NCT06663189","phase":"PHASE3","title":"Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-01","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":200},{"nctId":"NCT06705608","phase":"","title":"Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2003-01-01","conditions":"Multiple Sclerosis, Skin Cancer, Skin Cancer Melanoma","enrollment":4000},{"nctId":"NCT05811949","phase":"","title":"Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.","status":"COMPLETED","sponsor":"IRCCS Centro Neurolesi Bonino Pulejo","startDate":"2021-02-24","conditions":"Multiple Sclerosis","enrollment":52},{"nctId":"NCT06513533","phase":"PHASE2, PHASE3","title":"Dimethyl Fumarate in Adrenomyeloneuropathy","status":"RECRUITING","sponsor":"Pujol, Aurora, M.D.","startDate":"2024-04-23","conditions":"Adrenomyeloneuropathy Without Cerebral Involvement","enrollment":40},{"nctId":"NCT04792567","phase":"PHASE4","title":"Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-04-19","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":41},{"nctId":"NCT04472975","phase":"","title":"Prescription Drug Safety and Effectiveness in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"1996-01-01","conditions":"Multiple Sclerosis","enrollment":35000},{"nctId":"NCT06385197","phase":"NA","title":"Improving the Effect of Multiple Sclerosis Drugs by Chronobiology","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2022-05-08","conditions":"Multiple Sclerosis","enrollment":8},{"nctId":"NCT03399981","phase":"","title":"Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-06-01","conditions":"Progressive Multifocal Leukoencephalopathy","enrollment":80327},{"nctId":"NCT05417269","phase":"PHASE1, PHASE2","title":"IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Imcyse SA","startDate":"2022-04-12","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":150},{"nctId":"NCT05112484","phase":"","title":"Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Ostrava","startDate":"2024-06","conditions":"Multiple Sclerosis","enrollment":600},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04891497","phase":"PHASE2","title":"Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke","status":"WITHDRAWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2021-06-01","conditions":"Acute Ischemic Stroke","enrollment":""},{"nctId":"NCT04890379","phase":"PHASE2","title":"Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage","status":"WITHDRAWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2021-06-01","conditions":"Intracerebral Hemorrhage","enrollment":""},{"nctId":"NCT04890353","phase":"PHASE1, PHASE2","title":"Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke","status":"TERMINATED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2021-12-01","conditions":"Acute Ischemic Stroke","enrollment":2},{"nctId":"NCT04756687","phase":"","title":"Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera","status":"COMPLETED","sponsor":"Biogen","startDate":"2021-03-10","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":1507},{"nctId":"NCT04468165","phase":"","title":"Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region","status":"COMPLETED","sponsor":"Hikma Pharmaceuticals LLC","startDate":"2021-02-23","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":160},{"nctId":"NCT00168701","phase":"PHASE2","title":"Efficacy and Safety of BG00012 in MS","status":"COMPLETED","sponsor":"Biogen","startDate":"2004-10-01","conditions":"Multiple Sclerosis","enrollment":260},{"nctId":"NCT01281111","phase":"PHASE1","title":"Alternate Dosing Regimens of BG00012 in Healthy Volunteers","status":"COMPLETED","sponsor":"Biogen","startDate":"2011-02-01","conditions":"Healthy","enrollment":56},{"nctId":"NCT05779449","phase":"NA","title":"Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in MS","status":"RECRUITING","sponsor":"Neuromed IRCCS","startDate":"2023-07-26","conditions":"Patient Participation","enrollment":100},{"nctId":"NCT04221191","phase":"","title":"Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP","status":"COMPLETED","sponsor":"Biogen","startDate":"2019-08-19","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":353},{"nctId":"NCT05959759","phase":"PHASE4","title":"Dimethyl Fumarate Treatment for Intracranial Unruptured Aneurysms.","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2023-07-31","conditions":"Intracranial Aneurysm, Aneurysm, Brain, Inflammation Vascular","enrollment":60},{"nctId":"NCT03870763","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants","status":"TERMINATED","sponsor":"Biogen","startDate":"2019-03-19","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":11},{"nctId":"NCT02047097","phase":"","title":"Dimethyl Fumarate (DMF) Observational Study","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-11-19","conditions":"Multiple Sclerosis","enrollment":5487},{"nctId":"NCT04796584","phase":"","title":"Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication","status":"TERMINATED","sponsor":"Providence Health & Services","startDate":"2022-07-11","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT02546440","phase":"PHASE2","title":"Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)","status":"COMPLETED","sponsor":"Universitätsmedizin Mannheim","startDate":"2015-09","conditions":"Cutaneous T Cell Lymphoma","enrollment":25},{"nctId":"NCT05762003","phase":"","title":"Czech Pharmaco-epidemiological Study on Disease Modifying Drugs","status":"COMPLETED","sponsor":"IMPULS Endowment Fund","startDate":"2019-01-01","conditions":"Multiple Sclerosis","enrollment":17478},{"nctId":"NCT04570670","phase":"PHASE1","title":"Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects","status":"COMPLETED","sponsor":"Banner Life Sciences LLC","startDate":"2017-01-06","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":50},{"nctId":"NCT05528666","phase":"","title":"Risk Perception in Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-09","conditions":"Multiple Sclerosis","enrollment":4361},{"nctId":"NCT05576779","phase":"","title":"Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-03","conditions":"Multiple Sclerosis","enrollment":2101},{"nctId":"NCT04676204","phase":"","title":"Relationship Between Oral DMT Burden and Adherence in MS","status":"ENROLLING_BY_INVITATION","sponsor":"Monash University","startDate":"2020-09-25","conditions":"Multiple Sclerosis, Adherence, Medication","enrollment":323},{"nctId":"NCT04834401","phase":"","title":"Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis","status":"COMPLETED","sponsor":"St. Barnabas Medical Center","startDate":"2021-03-22","conditions":"Multiple Sclerosis, Covid19","enrollment":45},{"nctId":"NCT02634307","phase":"PHASE3","title":"A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-12-10","conditions":"Multiple Sclerosis","enrollment":1057},{"nctId":"NCT01911767","phase":"","title":"Biogen Multiple Sclerosis Pregnancy Exposure Registry","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-10-30","conditions":"Multiple Sclerosis, Exposure During Pregnancy","enrollment":408},{"nctId":"NCT04890366","phase":"PHASE1, PHASE2","title":"Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2021-12-01","conditions":"Acute Ischemic Stroke","enrollment":50},{"nctId":"NCT04263610","phase":"PHASE4","title":"Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2019-09-04","conditions":"Plaque Psoriasis","enrollment":190},{"nctId":"NCT02739542","phase":"PHASE4","title":"Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-03-19","conditions":"Multiple Sclerosis (MS)","enrollment":87},{"nctId":"NCT05366036","phase":"","title":"A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2017-06-14","conditions":"Multiple Sclerosis, Relapsing-remitting","enrollment":172},{"nctId":"NCT02981082","phase":"PHASE1","title":"Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Robert Lafyatis","startDate":"2016-12","conditions":"Systemic Sclerosis, Pulmonary; Hypertension","enrollment":6},{"nctId":"NCT04925778","phase":"","title":"Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate","status":"WITHDRAWN","sponsor":"Banner Life Sciences LLC","startDate":"2021-06-30","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":""},{"nctId":"NCT02746744","phase":"PHASE3","title":"RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.","status":"COMPLETED","sponsor":"Anders Svenningsson","startDate":"2016-05","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":200},{"nctId":"NCT02471560","phase":"PHASE4","title":"Tecfidera and the Gut Microbiota","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-11-06","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":36},{"nctId":"NCT03101735","phase":"","title":"Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece","status":"COMPLETED","sponsor":"Genesis Pharma CNS & Specialty","startDate":"2016-09-23","conditions":"RRMS","enrollment":455},{"nctId":"NCT02907177","phase":"PHASE3","title":"Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)","status":"TERMINATED","sponsor":"Actelion","startDate":"2017-03-30","conditions":"Multiple Sclerosis","enrollment":136},{"nctId":"NCT03526224","phase":"","title":"Teriflunomide Tecfidera LMCE","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2018-06-14","conditions":"Tecfidera, Teriflunomide","enrollment":120},{"nctId":"NCT00835770","phase":"PHASE3","title":"BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-02-03","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":1736},{"nctId":"NCT02959658","phase":"PHASE2","title":"Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2016-12","conditions":"Primary Progressive Multiple Sclerosis","enrollment":54},{"nctId":"NCT03308994","phase":"","title":"Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2017-11-01","conditions":"C10.114.375.500","enrollment":650},{"nctId":"NCT04260711","phase":"NA","title":"Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-07-01","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive","enrollment":130},{"nctId":"NCT00273364","phase":"PHASE2","title":"Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-11-16","conditions":"Multiple Sclerosis","enrollment":110},{"nctId":"NCT03093324","phase":"PHASE3","title":"A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-03-15","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":506},{"nctId":"NCT02099370","phase":"","title":"Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2014-03","conditions":"Multiple Sclerosis","enrollment":34},{"nctId":"NCT02410278","phase":"PHASE4","title":"Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-03-12","conditions":"Multiple Sclerosis","enrollment":102},{"nctId":"NCT01930708","phase":"PHASE4","title":"A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-10-31","conditions":"Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis","enrollment":1114},{"nctId":"NCT04289675","phase":"","title":"Multiple Sclerosis: Chi3L1 and Treatment Efficacy","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2012-01-01","conditions":"Multiple Sclerosis","enrollment":63},{"nctId":"NCT02951533","phase":"PHASE3","title":"A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2016-12-12","conditions":"Psoriasis","enrollment":119},{"nctId":"NCT04022473","phase":"PHASE1","title":"Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers","status":"COMPLETED","sponsor":"Banner Life Sciences LLC","startDate":"2019-07-07","conditions":"Multiple Sclerosis","enrollment":210},{"nctId":"NCT02201849","phase":"PHASE1","title":"A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-07","conditions":"Multiple Sclerosis","enrollment":104},{"nctId":"NCT02555215","phase":"PHASE3","title":"Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-02-22","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":20},{"nctId":"NCT03345940","phase":"PHASE4","title":"Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis","status":"TERMINATED","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2017-04-30","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":55},{"nctId":"NCT02634801","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-01-20","conditions":"Plaque Psoriasis","enrollment":162},{"nctId":"NCT02784834","phase":"PHASE1","title":"Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL","status":"TERMINATED","sponsor":"Michael Choi","startDate":"2016-06","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":2},{"nctId":"NCT03255382","phase":"PHASE3","title":"A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-08-22","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT02749396","phase":"","title":"EPID Multiple Sclerosis Pregnancy Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-02","conditions":"Multiple Sclerosis","enrollment":2089},{"nctId":"NCT02337426","phase":"PHASE1","title":"Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2015-02-13","conditions":"Adult Brain Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma","enrollment":12},{"nctId":"NCT02525874","phase":"PHASE3","title":"Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-08-11","conditions":"Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis","enrollment":218},{"nctId":"NCT02901106","phase":"PHASE4","title":"Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2017-05-23","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":11},{"nctId":"NCT01838668","phase":"PHASE3","title":"An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-03-28","conditions":"Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis","enrollment":225},{"nctId":"NCT02461069","phase":"PHASE4","title":"Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2015-05-06","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":67},{"nctId":"NCT02644083","phase":"","title":"Tecfidera and MRI for Brain Energy in MS","status":"TERMINATED","sponsor":"Oregon Health and Science University","startDate":"2016-02","conditions":"Multiple Sclerosis","enrollment":4},{"nctId":"NCT03284970","phase":"","title":"Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2017-08-23","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":34},{"nctId":"NCT03092544","phase":"PHASE4","title":"Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients","status":"UNKNOWN","sponsor":"Multiple Sclerosis Center of Northeastern New York","startDate":"2015-02","conditions":"Multiple Sclerosis","enrollment":57},{"nctId":"NCT02823951","phase":"","title":"Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®","status":"COMPLETED","sponsor":"IMS HEALTH GmbH & Co. OHG","startDate":"2016-02","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":479},{"nctId":"NCT00837785","phase":"PHASE1","title":"A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-02-28","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":48},{"nctId":"NCT02474082","phase":"PHASE3","title":"Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-04","conditions":"Psoriasis","enrollment":202},{"nctId":"NCT02410200","phase":"PHASE2","title":"Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-09-30","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1159,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tecfidera","DMF","dimethyl fumarate"],"phase":"marketed","status":"active","brandName":"BG00012 (DMF)","genericName":"BG00012 (DMF)","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BG00012 (dimethyl fumarate) activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway to reduce oxidative stress and neuroinflammation. Used for Relapsing-remitting multiple sclerosis (RRMS), Primary progressive multiple sclerosis (PPMS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}